Y-mAbs’ External Control Problems May Sink Neuroblastoma Candidate I-Omburtamab

 
• By Derrick Gingery
Neuroblastoma cells
The FDA has not approved a therapy for neuroblastoma with CNS/LM relapse. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers